Evidence map›Paper›PMID 30108330›Full record

ArticleBone marrow transplantation2019

Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades.

Masamitsu Yanada, Masayoshi Masuko, Jinichi Mori, Jun Aoki, Shohei Mizuno, Takahiro Fukuda, Kazuhiko Kakihana, Yukiyasu Ozawa, Shuichi Ota, Heiwa Kanamori and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Masamitsu YanadaAichi Cancer Center, Nagoya, Japan. myanada@aichi-cc.jp.
Masayoshi MasukoNiigata University Medical and Dental Hospital, Niigata, Japan.
Jinichi MoriJyoban Hospital Tokiwa Foundation, Fukushima, Japan.
Jun AokiYokohama City University Medical Center, Yokohama, Japan.
Shohei MizunoAichi Medical University, Nagakute, Japan.
Takahiro FukudaNational Cancer Center Hospital, Tokyo, Japan.
Kazuhiko KakihanaTokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Yukiyasu OzawaJapanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Shuichi OtaSapporo Hokuyu Hospital, Sapporo, Japan.
Heiwa KanamoriKanagawa Cancer Center, Yokohama, Japan.
Takehiko MoriKeio University School of Medicine, Tokyo, Japan.
Hirohisa NakamaeGraduate School of Medicine, Osaka City University, Osaka, Japan.
Tetsuya EtoHamanomachi Hospital, Fukuoka, Japan.
Souichi ShiratoriHokkaido University Faculty of Medicine, Sapporo, Japan.
Tetsuo MaedaOsaka University Graduate School of Medicine, Osaka, Japan.
Koji IwatoHiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Tatsuo IchinoheHiroshima University Hospital, Hiroshima, Japan.
Yoshinobu KandaJichi Medical University, Shimotsuke, Japan.
Junji TanakaTokyo Women's Medical University, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Shingo YanoJikei University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It remains unclear how specific innovations in allogeneic hematopoietic cell transplantation (HCT) attained over the past decades have contributed to improvement in transplantation outcomes. To address this question, we conducted a registry-based study of adults with acute myeloid leukemia in first or second complete remission who underwent allogeneic HCT between 1994 and 2013 from a sibling (N = 1600) or unrelated (N = 2113) donor matched at the antigen level for HLA-A, -B, and -DR. Preliminary analysis led us to focus on comparisons between the 1994-2006 and 2007-2013 periods. Significant improvement in survival was observed in the later cohort compared to the earlier cohort for unrelated HCT (P = 0.004), but not for related HCT (P = 0.767). The improvement in unrelated HCT was solely due to diminished non-relapse mortality (P = 0.001), while incidence of relapse did not change over time (P = 0.934). The percentage of patients receiving transplants from 8/8-matched unrelated donors was significantly higher in the later cohort (P < 0.001), and their survival was significantly better than that of those undergoing mismatched unrelated HCT (P = 0.022). These findings suggest that advances in HLA-typing technology have been vital for improvement in transplantation outcomes.

Indexed as

AdolescentAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedSurvival AnalysisTime FactorsTransplantation ConditioningTransplantation, HomologousYoung Adult

Identifiers

PMID30108330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.